Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Raushan T Kurmasheva

Showing results (1-10 of 84) with videos related to

Pageof 9
Sort By:
Pharmacological Reviews|September 28, 2019
Challenges and Opportunities for Childhood Cancer Drug DevelopmentPeter J Houghton, Raushan T Kurmasheva
Current Opinion in Chemical Biology|July 27, 2007
Pediatric oncologyRaushan T Kurmasheva, Peter J Houghton
Cancer Chemotherapy and Pharmacology|May 20, 2016
Identifying novel therapeutic agents using xenograft models of pediatric cancerRaushan T Kurmasheva, Peter J Houghton
Biochimica Et Biophysica Acta|July 18, 2006
IGF-I mediated survival pathways in normal and malignant cellsRaushan T Kurmasheva, Peter J Houghton
Journal of Clinical Medicine|April 30, 2021
Developing New Agents for Treatment of Childhood Cancer: Challenges and Opportunities for Preclinical TestingSamson Ghilu, Raushan T Kurmasheva, Peter J Houghton
Cancer Cell|March 15, 2006
IRS-1: auditing the effectiveness of mTOR inhibitorsJohn B Easton, Raushan T Kurmasheva, Peter J Houghton
Molecular Cancer Therapeutics|May 8, 2007
Differential regulation of vascular endothelial growth factor by Akt and mammalian target of rapamycin inhibitors in cell lines derived from childhood solid tumorsRaushan T Kurmasheva, Franklin C Harwood, Peter J Houghton
Frontiers in Oncology|September 18, 2015
Preclinical Childhood Sarcoma Models: Drug Efficacy Biomarker Identification and ValidationBrian Geier, Dias Kurmashev, Raushan T Kurmasheva, et al.
Pediatric Blood & Cancer|October 22, 2020
In vivo evaluation of the EZH2 inhibitor (EPZ011989) alone or in combination with standard of care cytotoxic agents against pediatric malignant rhabdoid tumor preclinical models-A report from the Pediatric Preclinical Testing ConsortiumRaushan T Kurmasheva, Stephen W Erickson, Eric Earley, et al.
Molecular Cancer Therapeutics|December 23, 2011
Potent inhibition of angiogenesis by the IGF-1 receptor-targeting antibody SCH717454 is reversed by IGF-2Hemant K Bid, Jun Zhan, Doris A Phelps, et al.
Pageof 9

Showing results (1-10 of 84) with videos related to

Sort By:
Pageof 9
Pharmacological Reviews|September 28, 2019
Challenges and Opportunities for Childhood Cancer Drug DevelopmentPeter J Houghton, Raushan T Kurmasheva
Current Opinion in Chemical Biology|July 27, 2007
Pediatric oncologyRaushan T Kurmasheva, Peter J Houghton
Cancer Chemotherapy and Pharmacology|May 20, 2016
Identifying novel therapeutic agents using xenograft models of pediatric cancerRaushan T Kurmasheva, Peter J Houghton
Biochimica Et Biophysica Acta|July 18, 2006
IGF-I mediated survival pathways in normal and malignant cellsRaushan T Kurmasheva, Peter J Houghton
Journal of Clinical Medicine|April 30, 2021
Developing New Agents for Treatment of Childhood Cancer: Challenges and Opportunities for Preclinical TestingSamson Ghilu, Raushan T Kurmasheva, Peter J Houghton
Cancer Cell|March 15, 2006
IRS-1: auditing the effectiveness of mTOR inhibitorsJohn B Easton, Raushan T Kurmasheva, Peter J Houghton
Molecular Cancer Therapeutics|May 8, 2007
Differential regulation of vascular endothelial growth factor by Akt and mammalian target of rapamycin inhibitors in cell lines derived from childhood solid tumorsRaushan T Kurmasheva, Franklin C Harwood, Peter J Houghton
Frontiers in Oncology|September 18, 2015
Preclinical Childhood Sarcoma Models: Drug Efficacy Biomarker Identification and ValidationBrian Geier, Dias Kurmashev, Raushan T Kurmasheva, et al.
Pediatric Blood & Cancer|October 22, 2020
In vivo evaluation of the EZH2 inhibitor (EPZ011989) alone or in combination with standard of care cytotoxic agents against pediatric malignant rhabdoid tumor preclinical models-A report from the Pediatric Preclinical Testing ConsortiumRaushan T Kurmasheva, Stephen W Erickson, Eric Earley, et al.
Molecular Cancer Therapeutics|December 23, 2011
Potent inhibition of angiogenesis by the IGF-1 receptor-targeting antibody SCH717454 is reversed by IGF-2Hemant K Bid, Jun Zhan, Doris A Phelps, et al.
Pageof 9